Attached files
| file | filename |
|---|---|
| 8-K - SURMODICS, INC. 8-K - SURMODICS INC | a50627342.htm |
Exhibit 99.1
SurModics Reports Second Quarter Fiscal 2013 Results
- GAAP Revenue Grows 12%
- Continuing Operations GAAP EPS Increases to $0.23
- Non-GAAP Continuing Operations EPS Increases 25% to $0.20
- Revenue and EPS Ranges for Full Year Reaffirmed
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--May 7, 2013--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industries, today announced results for its fiscal 2013 second quarter.
Second Quarter Revenue and Earnings Summary
Revenue for the second quarter totaled $13.7 million, a 12% increase from $12.2 million reported in the fiscal 2012 second quarter. Diluted earnings per share from continuing operations totaled $0.23 versus $0.11 in the prior-year period. On a non-GAAP basis, earnings per share from continuing operations were $0.20 in the 2013 second quarter.
Fiscal 2013 second quarter earnings per share include $0.03 per share of income tax benefits from capital loss carrybacks and retroactively reinstated R&D tax credits. Further, the prior-year quarterly period included an impairment charge related to a strategic investment of $0.8 million, or $0.05 per share.
Commenting on the results, SurModics’ President and Chief Executive Officer, Gary Maharaj said, “I am pleased with our team’s performance in the second quarter. We delivered double-digit gains in both revenue and earnings per share. Our strategy of focusing on SurModics’ core businesses continued to drive strong results in our two businesses. Both our Medical Device and In Vitro Diagnostic segments are executing our strategic initiatives as planned, and both reported solid year-over-year revenue gains.”
Medical Device Highlights
Revenue for the Medical Device business unit, which includes hydrophilic coatings and device drug delivery technologies, was $9.7 million, an 11% increase from $8.8 million in the fiscal second quarter of last year. Second quarter hydrophilic coating revenue increased 10% to $9.6 million compared with the year ago period. Medical Device generated $4.8 million of operating income during the quarter, a 16% increase from fiscal 2012.
Additional highlights include:
- Three medical device customers launching new products utilizing SurModics hydrophilic coatings; and
- Double-digit hydrophilic royalty growth in the key neurovascular and transcatheter valves growth segments.
In Vitro Diagnostics Highlights
For the second quarter, revenue for the In Vitro Diagnostics (IVD) business unit totaled $4.0 million, up 15% compared with the second quarter of fiscal 2012. The IVD business unit generated $1.3 million of operating income, the same as the year ago period, as the increase in gross margin from higher sales did not offset the higher operating expenses that stemmed from increased allocation of corporate expense, as well as additional hiring needed to support growth.
Additional highlights include:
- 10 consecutive quarters of year-over-year product revenue growth; and
- The addition of 16 new diagnostic test kit customers.
Discontinued Operations
During the fiscal 2013 second quarter, the Company realized discontinued operations income of almost $0.7 million, net of tax, primarily from the settlement of job incentive obligations with the City of Birmingham, Alabama.
Balance Sheet
As of March 31, 2013, the Company has $63.2 million of cash and investments. SurModics purchased 105,097 common shares for $2.7 million in the fiscal 2013 second quarter.
Full-Year Revenue and Earnings Outlook
SurModics reaffirms its previously stated fiscal 2013 outlook for revenue and earnings per share from continuing operations. Revenue from continuing operations is expected to be in the range of $55 million to $58 million. GAAP earnings per share from continuing operations are expected to be in the range of $ $0.86 to $0.99 per share. Per share information does not take into account any share repurchases that might occur during the balance of fiscal 2013. For fiscal 2012, SurModics reported revenue of $51.9 million and earnings per share from continuing operations of $0.58.
Maharaj concluded “We are off to a solid start in fiscal 2013 and remain confident in our ability to make progress on our stated strategic, operational and financial goals for the full year.”
Correction of Carrying Value of Strategic Investment in Prior Period
The accompanying financial tables reflect a $1.2 million adjustment to increase the carrying value of our strategic investments, recorded within other assets, and stockholders’ equity in the prior period balance sheet. This adjustment corrects and reduces an other than temporary impairment charge as of September 30, 2010, which was previously recorded during the fiscal fourth quarter ended September 30, 2010. The original other than temporary impairment charge did not sufficiently evaluate the impact of the proposed sale of a strategic investment subsidiary to an unrelated third party, in evaluating the value of the strategic investment. This transaction was consummated on February 1, 2011. The impact of this adjustment was not deemed to be material to the results of operations, total assets or stockholders’ equity for the previously reported periods. Further details of this adjustment will be included in our Quarterly Report on Form 10-Q for the period ended March 31, 2013.
Live Webcast
SurModics will host a webcast at 5 p.m. ET (4 p.m. CT) today to discuss second quarter results. To access the webcast, go to the Investors section of the Company’s website at www.surmodics.com and click on the webcast icon. A replay of the second quarter conference call will be available by dialing 800-406-7325 and entering conference call ID passcode 4593304. The audio replay will be available beginning at 7 p.m. ET on Tuesday, May 7, 2013, until 7 p.m. ET on Tuesday, May 14, 2013.
About SurModics, Inc.
SurModics’ mission is to exceed our customers’ expectations and enhance the well-being of patients by providing the world’s foremost, innovative surface modification technologies and in vitro diagnostic chemical components. The Company partners with the world’s leading and emerging medical device, diagnostic and life science companies to develop and commercialize innovative products designed to improve patient diagnosis and treatment. Core offerings include surface modification coating technologies that impart lubricity, prohealing, and biocompatibility capabilities; and components for in vitro diagnostic test kits and microarrays. SurModics is headquartered in Eden Prairie, Minnesota. For more information about the Company, visit http://www.surmodics.com. The content of SurModics’ website is not part of this press release or part of any filings that the Company makes with the SEC.
Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements. Statements that are not historical or current facts, including statements about beliefs and expectations regarding our ability to achieve sustainable long-term growth and value creation, our expectations regarding the Company’s performance in the near- and long-term, including our revenue and earnings expectations for fiscal 2013, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and important factors could cause actual results to differ materially from those anticipated, including (1) reliance on third parties (including our customers and licensees) and their failure to successfully develop, obtain regulatory approval for, market and sell products incorporating our technologies may adversely affect our business operations, our ability to realize the full potential of our pipeline, and our ability to achieve our corporate goals; (2) possible adverse market conditions and possible adverse impacts on our cash flows, and (3) the factors identified under “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2012, and updated in our subsequent reports filed with the SEC. These reports are available in the Investors section of our website at www.surmodics.com and at the SEC website at www.sec.gov. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update them in light of new information or future events.
Use of Non-GAAP Financial Information
In addition to reporting financial results in accordance with generally accepted accounting principles, or GAAP, SurModics is reporting non-GAAP financial results including non-GAAP net income and non-GAAP diluted net income per share. We believe that these non-GAAP measures provide meaningful insight into our operating performance excluding certain event-specific matters, and provide an alternative perspective of our results of operations. We use non-GAAP measures, including those set forth in this release, to assess our operating performance and to determine payout under our executive compensation programs. We believe that presentation of certain non-GAAP measures allows investors to review our results of operations from the same perspective as management and our board of directors and facilitates comparisons of our current results of operations. The method we use to produce non-GAAP results is not in accordance with GAAP and may differ from the methods used by other companies. Non-GAAP results should not be regarded as a substitute for corresponding GAAP measures but instead should be utilized as a supplemental measure of operating performance in evaluating our business. Non-GAAP measures do have limitations in that they do not reflect certain items that may have a material impact upon our reported financial results. As such, these non-GAAP measures presented should be viewed in conjunction with both our financial statements prepared in accordance with GAAP and the reconciliation of the supplemental non-GAAP financial measures to the comparable GAAP results provided for the specific periods presented, which are attached to this release.
| SurModics, Inc. and Subsidiaries | ||||||||||||||||||||
| Condensed Consolidated Statements of Income | ||||||||||||||||||||
|
(in thousands, except per share data) |
||||||||||||||||||||
|
Three Months Ended March 31, |
Six Months Ended March 31, |
|||||||||||||||||||
| 2013 | 2012 | 2013 | 2012 | |||||||||||||||||
| (Unaudited) | (Unaudited) | |||||||||||||||||||
| Revenue | ||||||||||||||||||||
| Royalties and license fees | $ | 6,951 | $ | 6,283 | $ | 14,467 | $ | 12,893 | ||||||||||||
| Product sales | 5,758 | 5,067 | 11,111 | 9,701 | ||||||||||||||||
| Research and development | 986 | 860 | 1,968 | 1,532 | ||||||||||||||||
| Total revenue | 13,695 | 12,210 | 27,546 | 24,126 | ||||||||||||||||
| Operating costs and expenses | ||||||||||||||||||||
| Product costs | 1,945 | 1,615 | 3,904 | 3,205 | ||||||||||||||||
| Research and development | 3,774 | 3,512 | 7,136 | 7,150 | ||||||||||||||||
| Selling, general and administrative | 3,847 | 3,394 | 7,500 | 6,860 | ||||||||||||||||
| Total operating costs and expenses | 9,566 | 8,521 | 18,540 | 17,215 | ||||||||||||||||
| Operating income from continuing operations | 4,129 | 3,689 | 9,006 | 6,911 | ||||||||||||||||
| Investment income | 56 | 143 | 127 | 281 | ||||||||||||||||
| Other income | 282 | 162 | 1,458 | 170 | ||||||||||||||||
| Impairment loss on investments | (129 | ) | (804 | ) | (129 | ) | (804 | ) | ||||||||||||
| Other income (loss), net | 209 | (499 | ) | 1,456 | (353 | ) | ||||||||||||||
| Income from continuing operations before income taxes | 4,338 | 3,190 | 10,462 | 6,558 | ||||||||||||||||
| Income tax provision | (918 | ) | (1,244 | ) | (2,794 | ) | (2,457 | ) | ||||||||||||
| Income from continuing operations | 3,420 | 1,946 | 7,668 | 4,101 | ||||||||||||||||
| Discontinued operations: | ||||||||||||||||||||
| Income (loss) from discontinued operations, net of taxes | 682 | (344 | ) | 682 | 1,261 | |||||||||||||||
| Income (loss) on sale of discontinued operations, net of taxes |
― |
121 |
― |
(933 | ) | |||||||||||||||
| Income (loss) from discontinued operations | 682 | (223 | ) | 682 | 328 | |||||||||||||||
| Net income | $ | 4,102 | $ | 1,723 | $ | 8,350 | $ | 4,429 | ||||||||||||
| Basic income (loss) per share: | ||||||||||||||||||||
| Continuing operations | $ | 0.23 | $ | 0.11 | $ | 0.52 | $ | 0.23 | ||||||||||||
| Discontinued operations | 0.05 | (0.01 | ) | 0.05 | 0.02 | |||||||||||||||
| Net income | $ | 0.28 | $ | 0.10 | $ | 0.57 | $ | 0.25 | ||||||||||||
| Diluted income (loss) per share: | ||||||||||||||||||||
| Continuing operations | $ | 0.23 | $ | 0.11 | $ | 0.52 | $ | 0.23 | ||||||||||||
| Discontinued operations | 0.05 | (0.01 | ) | 0.05 | 0.02 | |||||||||||||||
| Net income | $ | 0.28 | $ | 0.10 | $ | 0.56 | $ | 0.25 | ||||||||||||
| Weighted average number of shares outstanding: | ||||||||||||||||||||
| Basic | 14,622 | 17,519 | 14,639 | 17,498 | ||||||||||||||||
| Diluted | 14,914 | 17,632 | 14,871 | 17,575 | ||||||||||||||||
| SurModics, Inc. and Subsidiaries | ||||||||
| Condensed Consolidated Balance Sheets | ||||||||
|
(in thousands) |
||||||||
|
March 31, 2013 |
September 30, |
|||||||
| (Unaudited) | ||||||||
| Assets | ||||||||
| Cash and short term investments | $ | 35,684 | $ | 29,657 | ||||
| Accounts receivable | 4,911 | 5,069 | ||||||
| Inventories | 3,364 | 3,524 | ||||||
| Other current assets | 1,692 | 822 | ||||||
| Current assets of discontinued operations | 129 | 883 | ||||||
| Total current assets | 45,780 | 39,955 | ||||||
| Property and equipment, net | 13,214 | 13,610 | ||||||
| Long-term investments | 27,506 | 28,433 | ||||||
| Other assets | 21,093 | 22,321 | ||||||
| Total assets | $ | 107,593 | $ | 104,319 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities | $ | 3,197 | $ | 5,259 | ||||
| Current liabilities of discontinued operations | 271 | 1,640 | ||||||
| Total current liabilities | 3,468 | 6,899 | ||||||
| Other liabilities | 2,140 | 2,432 | ||||||
| Total stockholders’ equity | 101,985 | 94,988 | ||||||
| Total liabilities and stockholders’ equity | $ | 107,593 | $ | 104,319 | ||||
| SurModics, Inc. and Subsidiaries | ||||||||||
| Condensed Consolidated Statements of Cash Flows | ||||||||||
|
(in thousands) |
||||||||||
|
Six Months Ended March 31, |
||||||||||
| 2013 | 2012 | |||||||||
| (Unaudited) | ||||||||||
| Operating Activities: | ||||||||||
| Net income | $ | 8,350 | $ | 4,429 | ||||||
| Income from discontinued operations | (682 | ) | (1,261 | ) | ||||||
| Loss on sale of discontinued operations | ― | 933 | ||||||||
| Depreciation and amortization | 1,446 | 1,480 | ||||||||
| Stock-based compensation | 1,238 | 1,533 | ||||||||
| Gain on sale of available-for-sale securities and strategic investments | (1,458 | ) | (170 | ) | ||||||
| Net other operating activities | 492 | 552 | ||||||||
| Change in operating assets and liabilities: | ||||||||||
| Accounts receivable | 158 | (244 | ) | |||||||
| Accounts payable and accrued liabilities | (1,366 | ) | (3,159 | ) | ||||||
| Income taxes | (1,322 | ) | 2,739 | |||||||
| Net change in other operating assets and liabilities | (31 | ) | (658 | ) | ||||||
| Net cash provided by operating activities from continuing operations | 6,825 | 6,174 | ||||||||
| Investing Activities: | ||||||||||
| Net purchases of property and equipment | (1,239 | ) | (269 | ) | ||||||
| Cash (transferred to) received from discontinued operations | (86 | ) | 28,189 | |||||||
| Net other investing activities | 2,175 | 2,826 | ||||||||
| Net cash provided by investing activities from continuing operations | 850 | 30,746 | ||||||||
| Financing Activities: | ||||||||||
| Purchase of common stock to fund employee taxes | (39 | ) | (170 | ) | ||||||
| Repurchase of common stock | (2,681 | ) | ― | |||||||
| Net other financing activities | 42 | 217 | ||||||||
| Net cash (used in) provided by financing activities from continuing operations | (2,678 | ) | 47 | |||||||
| Net cash provided by continuing operations | 4,997 | 36,967 | ||||||||
| Discontinued operations: | ||||||||||
| Net cash used in operating activities | (86 | ) | (1,627 | ) | ||||||
| Net cash provided by investing activities | ― | 29,816 | ||||||||
| Net cash provided by (used in) financing activities | 86 | (28,189 | ) | |||||||
| Net cash provided by discontinued operations | ― | ― | ||||||||
| Net change in cash and cash equivalents | 4,997 | 36,967 | ||||||||
| Cash and Cash Equivalents: | ||||||||||
| Beginning of period | 15,540 | 23,217 | ||||||||
| End of period | $ | 20,537 |
$ |
60,184 | ||||||
| SurModics, Inc. and Subsidiaries | |||||||||||||||||||||||
| Supplemental Segment Information | |||||||||||||||||||||||
|
(in thousands) |
|||||||||||||||||||||||
|
(Unaudited) |
|||||||||||||||||||||||
| Three Months Ended March 31, | |||||||||||||||||||||||
| 2013 | 2012 | % Change | |||||||||||||||||||||
| Revenue | % of Total | % of Total | |||||||||||||||||||||
| Medical Device | $ | 9,735 | 71.1 | % | $ | 8,753 | 71.7 | % | 11.2 | % | |||||||||||||
| In Vitro Diagnostics | 3,960 | 28.9 | 3,457 | 28.3 | 14.6 | ||||||||||||||||||
| Total revenue | $ | 13,695 | 100.0 | % | $ | 12,210 | 100.0 | % | 12.2 | % | |||||||||||||
| Six Months Ended March 31, | |||||||||||||||||||||||
| 2013 | 2012 | % Change | |||||||||||||||||||||
| Revenue | % of Total | % of Total | |||||||||||||||||||||
| Medical Device | $ | 20,266 | 73.6 | % | $ | 17,620 | 73.0 | % | 15.0 | % | |||||||||||||
| In Vitro Diagnostics | 7,280 | 26.4 | 6,506 | 27.0 | 11.9 | ||||||||||||||||||
| Total revenue | $ | 27,546 | 100.0 | % | $ | 24,126 | 100.0 | % | 14.2 | % | |||||||||||||
|
Three Months Ended |
Six Months Ended |
||||||||||||||||||||||
| 2013 | 2012 | 2013 | 2012 | ||||||||||||||||||||
| Operating Income (Loss) | |||||||||||||||||||||||
| Medical Device | $ | 4,785 | $ | 4,121 | $ | 10,625 | $ | 8,053 | |||||||||||||||
| In Vitro Diagnostics | 1,267 | 1,271 | 2,018 | 2,177 | |||||||||||||||||||
| Corporate | (1,923 | ) | (1,703 | ) | (3,637 | ) | (3,319 | ) | |||||||||||||||
| Total operating income | $ | 4,129 | $ | 3,689 | $ | 9,006 | $ | 6,911 | |||||||||||||||
| SurModics, Inc. and Subsidiaries | ||||||||||||||
| Supplemental Non-GAAP Information | ||||||||||||||
| For the Three Months Ended March 31, 2013 | ||||||||||||||
|
(In thousands, except per share data) |
||||||||||||||
|
(Unaudited) |
||||||||||||||
|
As Reported |
Adjustments |
Adjusted |
||||||||||||
| Revenue | ||||||||||||||
| Royalties and license fees | $ | 6,951 | $ | 6,951 | ||||||||||
| Product sales | 5,758 | 5,758 | ||||||||||||
| Research and development | 986 | 986 | ||||||||||||
| Total revenue | $ | 13,695 | $ | 13,695 | ||||||||||
| Operating income | $ | 4,129 | $ | 4,129 | ||||||||||
| $ | 10 |
(3) |
||||||||||||
| Income from continuing operations | $ | 3,420 | $ | (412 | ) |
(4) |
$ | 3,018 | ||||||
| Diluted earnings per share from continuing operations(5) | $ | 0.23 | $ | 0.20 | ||||||||||
| (1) | Reflects operating results from our continuing operations in accordance with U.S. generally accepted accounting principles (“GAAP”). Our Pharmaceuticals segment results are presented as discontinued operations. | |
| (2) | Adjusted Non-GAAP amounts consider adjustments to reduce investment income associated with the sale of OctoPlus shares offset by an impairment loss on the Company’s investment in ViaCyte and the income tax provision has been adjusted for discrete income tax benefits recognized for the period presented as noted in detail in note (4) below. | |
| (3) | Reflects the pre-tax impact of the investment income adjustments noted in (2) above. | |
| (4) | Adjusted to reflect discrete income tax benefits of $261 associated with realization of capital loss carrybacks and $151 from the January 2013 signing of the American Taxpayer Relief Act of 2012 which retroactively reinstated federal R&D tax credits for calendar 2012. | |
| (5) | Diluted earnings per share from continuing operations is calculated using the diluted weighted average shares outstanding for the period presented. | |
| SurModics, Inc. and Subsidiaries | |||||||||||||
| Supplemental Non-GAAP Information | |||||||||||||
| For the Three Months Ended March 31, 2012 | |||||||||||||
|
(in thousands, except per share data) |
|||||||||||||
|
(Unaudited) |
|||||||||||||
|
As Reported |
Adjustments |
Adjusted |
|||||||||||
| Revenue | |||||||||||||
| Royalties and license fees | $ | 6,283 | $ | 6,283 | |||||||||
| Product sales | 5,067 | 5,067 | |||||||||||
| Research and development | 860 | 860 | |||||||||||
| Total revenue | $ | 12,210 | $ | 12,210 | |||||||||
| Operating income from continuing operations | $ | 3,689 |
$ |
804 |
$ | 3,689 | |||||||
| Income from continuing operations | $ | 1,946 |
(3) |
$ | 2,750 | ||||||||
| Diluted earnings per share from continuing operations(4) | $ | 0.11 | $ | 0.16 | |||||||||
| (1) | Reflects continuing operating results in accordance with U.S. generally accepted accounting principles (“GAAP”). | |
| (2) | Adjusted Non-GAAP amounts consider adjustments to the impairment loss on investment in the period in accordance with GAAP. | |
| (3) | Reflects the after tax impact of the adjustment associated with the $804 impairment loss on investment. The impairment loss on investment did not generate a tax benefit. | |
| (4) | Diluted net income per share from continuing operations is calculated using the diluted weighted average shares outstanding for the period presented. | |
| SurModics, Inc. and Subsidiaries | ||||||||||||||
| Supplemental Non-GAAP Information | ||||||||||||||
| For the Six Months Ended March 31, 2013 | ||||||||||||||
|
(In thousands, except per share data) |
||||||||||||||
|
(Unaudited) |
||||||||||||||
|
As Reported |
Adjustments |
Adjusted |
||||||||||||
| Revenue | ||||||||||||||
| Royalties and license fees | $ | 14,467 | $ | 14,467 | ||||||||||
| Product sales | 11,111 | 11,111 | ||||||||||||
| Research and development | 1,968 | 1,968 | ||||||||||||
| Total revenue | $ | 27,546 | $ | 27,546 | ||||||||||
| Operating income | $ | 9,006 | $ | 9,006 | ||||||||||
| $ | (1,164 | ) |
(3) |
|||||||||||
| Income from continuing operations | $ | 7,668 | $ | (412 | ) |
(4) |
$ | 6,092 | ||||||
| Diluted earnings per share from continuing operations(5) | $ | 0.52 | $ | 0.41 | ||||||||||
| (1) | Reflects operating results from our continuing operations in accordance with U.S. generally accepted accounting principles (“GAAP”). Our Pharmaceuticals segment results are now presented as discontinued operations. | |
| (2) | Adjusted Non-GAAP amounts consider adjustments to investment income associated with the sale of Vessix Vascular and OctoPlus shares offset by an impairment loss on the Company’s investment in ViaCyte and the income tax provision has been adjusted for discrete income tax benefits recognized for the period presented as noted in detail in note (4) below. | |
| (3) | Reflects the pre-tax impact of the investment income adjustments noted in (2) above | |
| (4) | Adjusted to reflect discrete income tax benefits of $261 associated with realization of capital loss carrybacks and $151 from the January 2013 signing of the American Taxpayer Relief Act of 2012 which retroactively reinstated federal R&D tax credits for calendar 2012. | |
| (5) | Diluted earnings per share from continuing operations is calculated using the diluted weighted average shares outstanding for the period presented. | |
| SurModics, Inc. and Subsidiaries | |||||||||||||
| Supplemental Non-GAAP Information | |||||||||||||
| For the Six Months Ended March 31, 2012 | |||||||||||||
|
(in thousands, except per share data) |
|||||||||||||
|
(Unaudited) |
|||||||||||||
|
As Reported |
Adjustments |
Adjusted |
|||||||||||
| Revenue | |||||||||||||
| Royalties and license fees | $ | 12,893 | $ | 12,893 | |||||||||
| Product sales | 9,701 | 9,701 | |||||||||||
| Research and development | 1,532 | 1,532 | |||||||||||
| Total revenue | $ | 24,126 | $ | 24,126 | |||||||||
| Operating income from continuing operations | $ | 6,911 | $ | 6,911 | |||||||||
| Income from continuing operations | $ | 4,101 | $ | 804 |
(3) |
$ | 4,905 | ||||||
| Diluted earnings per share from continuing operations(4) | $ | 0.23 | $ | 0.28 | |||||||||
| (1) | Reflects continuing operating results in accordance with U.S. generally accepted accounting principles (“GAAP”). | |
| (2) | Adjusted Non-GAAP amounts consider adjustments to the impairment loss on investment in the period in accordance with GAAP. | |
| (3) | Reflects the after tax impact of the adjustments associated with the $804 impairment loss on investment. The impairment loss on investment did not generate a tax benefit. | |
| (4) | Diluted net income per share from continuing operations is calculated using the diluted weighted average shares outstanding for the period presented. | |
CONTACT:
SurModics, Inc.
Andy LaFrence, 952-500-7000
Vice
President of Finance and Chief Financial Officer